Abstract 623P
Background
Cancer ranks second globally in causes of death, accounting for 21% of all fatalities. However, many types of cancer can be cured if diagnosed and treated during early stages. We propose a liquid biopsy cancer analysis method that uses deep learning and a methylation-sensitive restriction enzyme digestion followed by sequencing method to detect and classify the most common cancers worldwide at early stages.
Methods
We developed a selective methylation sensitive restriction enzyme sequencing (MRE-Seq) method combined with a prediction model based on deep neural network (DNN) learning on data from 63,266 CpG sites to identify global hypomethylation patterns. The methylation dataset was made from 96 colon cancer samples, 95 lung cancer samples, 122 gastric cancer samples, 136 breast cancer samples, and 183 control samples. To eliminate batch bias, the ANOVA test was performed during feature selection. A DNN was adopted as a classifier, and 5-fold cross validation was performed to verify the classification performance.
Results
Across four cancer types, colorectal cancer had the highest predictive performance at 0.98, followed by breast cancer at 0.97, gastric cancer at 0.96, and lung cancer at 0.93. At 95% specificity, the sensitivity for detecting early-stage cancers varied widely, with lung cancer at 50% and breast cancer at 83%. Two different metrics were used to evaluate the model's performance. The cancer classifier (performance in detecting cancer) had a sensitivity of 95.1% and a specificity of 66.7%, indicating better performance in correctly identifying cancer samples. The cancer type classifier (performance in classifying the cancer type) utilized the precision metric to evaluate the accuracy of cancer classification. Notably, breast cancer achieved the highest precision at 95.8%, followed by lung cancer at 83.3%, gastric cancer at 79.1%, and colon cancer at 69.0%.
Conclusions
The proposed classification model based on the MRE-Seq method can reliably identify cancer and normal samples and differentiate between different cancer types using only methylation information obtained from patient's blood. This approach could be used in clinical practices to help medical experts diagnose cancer earlier and at the individual level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract